Showing 4951-4960 of 9743 results for "".
- Valeant Names Joseph C. Papa as Chairman and CEOhttps://practicaldermatology.com/news/valeant-names-joseph-c-papa-as-chairman-and-ceo/2458593/Valeant Pharmaceuticals International, Inc's Board of Directors has named Joseph C. Papa to become its Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. He will join Valeant from Perrigo Company plc, a leading global health
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- Estée Lauder's Newest Collection Embraces Gen Yhttps://practicaldermatology.com/news/este-lauders-newest-collection-embraces-gen-y/2458652/Estee Lauder’s latest collection is all about the millennials. Fronted by guest editors Kendall Jenner and Irene Kim, the Estée Edit by Estée Lauder comprises 82 makeup and skincare products. The collection is inspired by Estée&rs
- FDA Approves Allergan's Aczone Gel, 7.5% for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-allergans-aczone-gel-75-for-acne-vulgaris/2458681/The FDA approved Allergn’s Aczone (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. Aczone Gel, 7.5% delivers proven efficacy to treat both inflammatory and non-inflammatory acne, with a new concentration of dapsone in just once-a-day
- Botox Helps Fuel Allergan's “Better-Than-Expected” Q4 Earningshttps://practicaldermatology.com/news/botox-helps-fuel-allergans-better-than-expected-q4-earnings/2458687/Allergan is reporting “better-than-expected” fourth-quarter earnings, largely fueled by Botox. The company saw a 74 percent increase in Q4 net revenue to $4.2 Billion for Q4 2015, topping the nearly $4.18 billion consensus estimate of S&a
- Tempted by Temptu to Debut at AAD Annual Meetinghttps://practicaldermatology.com/news/tempted-by-temptu-to-debut-at-aad-annual-meeting/2458691/At the upcoming 2016 AAD annual meeting, TEMPTU introduces its groundbreaking TEMPTU Air, the first handheld airbrush makeup device for skin perfection. Using the company’s patented Airpod and Atomized AirFlow™ Technology, TEMPTU Air delivers a micro-fine mist that floa
- Pfizer Outlines Post-Allergan Deal Leadership Team Changeshttps://practicaldermatology.com/news/pfizer-outlines-post-allergan-deal-leadership-team-changes/2458709/Brent Saunders will become President and Chief Operating Officer of the combined Pfizer and Allergan company following the close of the merger deal. In this role, he will over see Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions. The c
- FDA Awards Tentative Approval for Zenavod to Treat Rosaceahttps://practicaldermatology.com/news/fda-awards-tentative-approval-for-zenavod-to-treat-rosacea/2458711/The FDA awarded Dr. Reddy's Laboratories tentative approval for Zenavod™ (doxycycline) Capsules, 40mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Promius™ Pharma, LLC, t